2022 (857)
2023 (2384)
2024 (1325)
2025 (1122)
Bruce Willis 密歇根大學神經科醫生
University of Michigan
Sami Barmada, Professor of Neurology: sbarmada@nospam.umich.edu
Judith Heidebrink, Professor of Neurology: jheide@med.umich.edu
Henry Paulson , Professor of Neurology: henryp@umich.edu
Noah Fromson , Reporter; fromsonn@med.umich.edu
布魯斯·威利斯確診額顳葉癡呆：密歇根大學神經科醫生可就此疾病發表評論
2023年2月17日
https://news.umich.edu/bruce-willis-frontotemporal-dementia-diagnosis-u-m-neurologists-can-comment-on-ftd/
諾亞·弗羅姆森，fromsonn@med.umich.edu
聯係人：伯尼·德格羅特
專家建議
著名演員布魯斯·威利斯的家人宣布，他被診斷患有額顳葉癡呆（FTD）。去年，他被診斷出患有失語症，這可能是FTD的早期症狀。
鑒於這一新的診斷，密歇根大學健康中心（密歇根醫學）的神經科醫生可以就FTD發表看法。FTD最常發生於40歲以上的人群。
薩米·巴爾馬達是安吉拉·多布森·韋爾奇和林登·韋爾奇神經病學研究教授。他的研究重點是額顳葉癡呆 (FTD) 與一種相關的退行性疾病——肌萎縮側索硬化症 (ALS) 之間的重疊之處。他的研究結合了基礎生物學、轉化研究和技術開發，旨在尋找治療 ALS 和 FTD 的新型有效療法。
朱迪思·海德布林克 (Judith Heidebrink) 是密歇根大學阿爾茨海默病中心臨床核心負責人之一，也是理查德·D·和凱瑟琳·M·奧康納神經病學研究教授。她參與癡呆症的合作臨床試驗已有 20 餘年，其中包括專注於阿爾茨海默病預防和治療的研究。
亨利·保爾森 (Henry Paulson) 是密歇根大學阿爾茨海默病中心主任，也是露西爾·格羅夫神經病學教授。他的研究和臨床興趣集中於與年齡相關的神經退行性疾病的病因和治療，尤其關注多聚穀氨酰胺疾病、阿爾茨海默病和額顳葉癡呆。他的實驗室還幫助開創了基因沉默方法作為治療由“有毒”突變基因引起的多種神經係統疾病的潛在療法的應用。
Bruce Willis frontotemporal dementia diagnosis: U-M neurologists can comment on FTD
February 17, 2023
https://news.umich.edu/bruce-willis-frontotemporal-dementia-diagnosis-u-m-neurologists-can-comment-on-ftd/
Noah Fromson, 216-509-8604, fromsonn@med.umich.edu
Contact: Bernie DeGroat
EXPERTS ADVISORY
The family of Bruce Willis has announced that the celebrated actor has frontotemporal dementia, or FTD. Last year, he was diagnosed with aphasia, which can be an early sign of FTD.
In wake of the new diagnosis, neurologists from University of Michigan Health, Michigan Medicine, are able to speak about FTD, which is most commonly diagnosed in people over the age of 40.
Sami Barmada is the Angela Dobson Welch and Lyndon Welch Research Professor of Neurology. His work centers on the overlap between FTD and a related degenerative condition, amyotrophic lateral sclerosis, or ALS. His work combines basic biology with translational research and technology development to identify new and effective treatments for both ALS and FTD.
Judith Heidebrink is the clinical core co-lead of the Michigan Alzheimer’s Disease Center and the Richard D. and Katherine M. O’Connor Research Professor of Neurology. She has been involved in collaborative clinical trials in dementia for more than 20 years, including studies focusing on the prevention and treatment of Alzheimer’s dementia.
Henry Paulson is director of the Michigan Alzheimer’s Disease Center and the Lucile Groff Professor of Neurology. His research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer’s disease and frontotemporal dementia. His lab also helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by “toxic” mutant genes.
